Nieuws en video's - ABLIVA AB [CBOE]

Edison Investment Research Limited Edison Investment Research Limited: Edison issues update on Abliva (NVP) 26-Jun-2020 / 12:41 GMT/BST London, UK, 26 June 2020 Edison issues update on Abliva (NVP) The rights issue announced on 19 February 2020 is now complete with 90% of the total amount of offered shares subscribed raising a total SEK67m. A positive surprise was the announcement that Nordic life sciences investor Hadean Ventures also decided to invest via a direct private placement of SEK20m....

NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire STOCKHOLM, Feb. 19, 2020 STOCKHOLM , Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVive completes recruitment of healthy volunteers in the second part of its ongoing KL1333 clinical Phase Ia/b study NV354 NeuroVive initiates NV354...

NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire STOCKHOLM, Feb. 19, 2020 STOCKHOLM , Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVive completes recruitment of healthy volunteers in the second part of its ongoing KL1333 clinical Phase Ia/b study NV354 NeuroVive initiates NV354...

NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire STOCKHOLM, Feb. 19, 2020 STOCKHOLM , Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVive completes recruitment of healthy volunteers in the second part of its ongoing KL1333 clinical Phase Ia/b study NV354 NeuroVive initiates NV354...

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire LUND, Sweden, Dec. 20, 2019 LUND, Sweden , Dec. 20, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the completed recruitment of healthy volunteers in the second part of the company's ongoing Phase Ia/b clinical study with candidate drug KL1333, in development for chronic oral treatment of primary mitochondrial disease. The first...

NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire LUND, Sweden, Dec. 16, 2019 LUND, Sweden , Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License Agreement with CicloMulsion AG under which NeuroVive licensed the rights to use and develop products based on a...

NeuroVive Pharmaceutical AB Interim Report January - September 2019 Continued Progress in KL1333 PR Newswire STOCKHOLM, Nov. 20, 2019 STOCKHOLM , Nov. 20, 2019 /PRNewswire/ -- Important events July - September NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. Financial information third quarter (July- September 2019 ) Net revenues: KSEK 0 (0) Other operating income: KSEK 1,500 (0)...

NeuroVive Pharmaceutical AB Interim Report January - September 2019 PR Newswire STOCKHOLM, Nov. 20, 2019 - Continued Progress in KL1333 STOCKHOLM , Nov. 20, 2019 /PRNewswire/ -- Important events July - September NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. Financial information third quarter (July- September 2019 ) Net revenues: KSEK 0 (0) Other operating income: KSEK 1,500 (0)...

NeuroVive Pharmaceutical AB Interim Report January - September 2019 Continued Progress in KL1333 PR Newswire STOCKHOLM, Nov. 20, 2019 STOCKHOLM , Nov. 20, 2019 /PRNewswire/ -- Important events July - September NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. Financial information third quarter (July- September 2019 ) Net revenues: KSEK 0 (0) Other operating income: KSEK 1,500 (0)...

NeuroVive Pharmaceutical AB Interim Report January - June 2019 Focus on genetic mitochondrial diseases PR Newswire STOCKHOLM, Aug. 21, 2019 STOCKHOLM , Aug. 21, 2019 /PRNewswire/ -- Important events April - June The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT. The Supreme Court delivers its ruling concerning arbitration between NeuroVive and CicloMulsion AG....

NeuroVive Pharmaceutical AB Interim Report January - June 2019 PR Newswire STOCKHOLM, Aug. 21, 2019 Focus on genetic mitochondrial diseases STOCKHOLM , Aug. 21, 2019 /PRNewswire/ -- Important events April – June The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT. The Supreme Court delivers its ruling concerning arbitration between NeuroVive and CicloMulsion...

NeuroVive Pharmaceutical AB Interim Report January - June 2019 Focus on genetic mitochondrial diseases PR Newswire STOCKHOLM, Aug. 21, 2019 STOCKHOLM , Aug. 21, 2019 /PRNewswire/ -- Important events April – June The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT. The Supreme Court delivers its ruling concerning arbitration between NeuroVive and CicloMulsion...

Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019 PR Newswire LUND, Sweden, Aug. 20, 2019 LUND, Sweden , Aug. 20, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company will host a Capital Markets Day in Stockholm on 9 October, 2019 , for investors, analysts and media. Presentations will be made by members of NeuroVive's management and board as well as by external authorities in genetic...

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation PR Newswire LUND, Sweden, July 27, 2019 LUND, Sweden , July 27, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to severe traumatic brain injury, TBI, has received Fast Track designation from the US Food and Drug Administration, FDA, facilitating its clinical development and path forwards to...

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study PR Newswire LUND, Sweden, 4 July 2019 LUND, Sweden , 4 July 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study with KL1333, NeuroVive's candidate drug for chronic treatment of genetic mitochondrial diseases, following successful completion of the first part. NeuroVive has now...

NeuroVive Pharmaceutical AB Interim Report January - March 2019 First subjects enrolled in the KL1333 study PR Newswire STOCKHOLM, May 21, 2019 STOCKHOLM , May 21, 2019 /PRNewswire/ -- Important events January- March 2019 NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study. NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds. NeuroVive receives SEK 28.2 Million in a directed new share issue. NeuroVive enters commercial partnership with Oroboros...

NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA PR Newswire LUND, Sweden, May 10, 2019 LUND, Sweden , May 10, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT in development for treatment of moderate to severe traumatic brain...

NeuroVive Pharmaceutical AB Publishes 2018 Annual Report PR Newswire LUND, Sweden, 25 March 2019 LUND, Sweden , 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website www.neurovive.com . This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was...

NeuroVive Pharmaceutical AB Publishes 2018 Annual Report PR Newswire LUND, Sweden, 25 March 2019 LUND, Sweden , 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website www.neurovive.com . This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was...

NeuroVive Pharmaceutical AB Publishes 2018 Annual Report PR Newswire LUND, Sweden, 25 March 2019 LUND, Sweden , 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website www.neurovive.com . This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was...